We could not find any results for:
Make sure your spelling is correct or try broadening your search.
cs PLC - Cambridgeshire, England-based biopharmaceutical company - Signs licensing agreement for its AT351 liquid drug ...
Arecor Therapeutics PLC 30 December 2024 Arecor Therapeutics plc ("Arecor" or the "Group") ARECOR SIGNS EXCLUSIVE LICENSING AGREEMENT FOR READY-TO-DILUTE FORMULATION OF SPECIALITY HOSPITAL...
Arecor Therapeutics PLC 02 December 2024 Arecor Therapeutics plc ("Arecor" or "the Company") Grant of Options and PDMR Dealing Cambridge, UK, 2 December 2024: Arecor Therapeutics plc...
cs PLC - biopharmaceutical company based in Little Chesterford, England - Announces hiring of David Ellam as interim c ...
Arecor Therapeutics PLC 18 November 2024 Arecor Therapeutics plc ("Arecor" or "the Company") APPOINTMENT OF INTERIM CHIEF FINANCIAL OFFICER Cambridge, UK, 18 November 2024: Arecor...
Arecor Therapeutics PLC 27 September 2024 Arecor Therapeutics plc ("Arecor" or the "Group") Arecor to present on Investor Meet Company platform Cambridge, UK, 27 September 2024: Arecor...
The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported b ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 4.5 | 6.47482014388 | 69.5 | 75 | 69.5 | 7025 | 73.83580682 | DE |
4 | -2.5 | -3.26797385621 | 76.5 | 78 | 62.5 | 6676 | 70.85856721 | DE |
12 | 5 | 7.24637681159 | 69 | 78 | 62.5 | 6812 | 73.50625073 | DE |
26 | -46 | -38.3333333333 | 120 | 120 | 62.5 | 8460 | 76.80536512 | DE |
52 | -106 | -58.8888888889 | 180 | 182 | 62.5 | 11514 | 119.62254209 | DE |
156 | -326 | -81.5 | 400 | 420 | 62.5 | 6796 | 178.83876539 | DE |
260 | -163.5 | -68.8421052632 | 237.5 | 460 | 62.5 | 7578 | 207.52743979 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions